Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences

SAN DIEGO – April 13, 2016Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that new results from the clinical investigation of Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine) for the treatment of recurrent high grade glioma will be presented at the 84th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be held April 30-May 4 in Chicago.

In addition, preclinical data supporting the combination of Toca 511 & Toca FC with checkpoint inhibitors, and demonstrating increased survival in colorectal cancer, will be presented at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 16-20 in New Orleans. Tocagen’s management team will also participate in a panel discussion at the Alliance for Cancer Gene Therapy (ACGT) scientific symposium, to be held April 14 in New York City, and present new preclinical and clinical data at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting, to be held May 4-7 in Washington D.C.

Details of the AANS presentations are as follows:

Presentation Type: Oral presentation
Title: Intravenous Toca 511 Delivery Leads to Viral DNA in Resected High Grade Glioma (HGG)
Date and Time: Monday, May 2, 2:00-5:30 p.m. ET
Presenter: Steven N. Kalkanis M.D., chair of the department of neurosurgery and co-director of the Neuroscience Institute at Henry Ford Hospital

Presentation Type: Oral presentation
Title: Toca 511 Followed by Toca FC in Subjects with Recurrent High Grade Glioma (rHGG)
Date and Time: Monday, May 2, 2:00-5:30 p.m. ET
Presenter: Manish Aghi, M.D., Ph.D., associate professor of neurological surgery at University of California, San Francisco

Details of the AACR presentations are as follows:

Abstract Number: 1413
Presentation Type: Poster
Title: Treatment of Mouse Liver and Brain Colon Cancer Metastases with Toca 511 and 5-fluorocytosine for Intratumoral Production of 5-fluorouracil Leads to Increased Survival, Induction of Anti-Tumor Immune Responses, and Reduction of MDSC
Date and Time: Monday, April 18, 8:00 a.m.-12:00 p.m. CT
Presenter: Maria Rodriguez-Aguirre, research associate at Tocagen

Abstract Number: 3212
Presentation Type: Poster
Title: Combining Toca 511 and 5-fluorocytosine with αPD-1 or αCTLA-4 Antibody Significantly Reduces Tumor Burden Compared to Either Checkpoint Inhibitor Alone or in Combination in a Subcutaneous Mouse Model of Glioma
Date and Time: Monday, April 19, 8:00 a.m.-12:00 pm. CT
Presenter: Leah Mitchell, Ph.D., research scientist at Tocagen

Details of the presentation at ACGT are as follows:

Presentation Type: Panel discussion
Panel Title: Clinical Development of Cell and Gene Therapy: Overview of What’s Hot in Clinical Development and the Most Important Developments Yet to Come
Date and Time: Thursday, April 14, 2:15-4:00 p.m. ET
Participant: Douglas J. Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen

Details of the presentations at ASGCT are as follows:

Abstract Number: 61
Presentation Type: Oral presentation
Title: Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High-Grade Glioma: Clinical Update, Molecular Analysis, and Proposed Mechanism of Action
Date and Time: Wednesday, May 4, 3:30-5:30 p.m. ET
Presenter: Douglas J. Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen

Abstract Number: 205
Presentation Type: Poster
Title: Cytotoxic and immunotherapeutic Effects of Toca 511 and 5-fluorocytosine in an Intraperitoneal Model of Metastatic Colorectal Cancer
Date and Time: Wednesday, May 4, 5:30-7:30 p.m. ET
Lead Author: Kader Yagiz, Ph.D., research scientist at Tocagen

Abstract Number: 403
Presentation Type: Poster
Title: Toca Retroviral Replicating Vector in Tumor and Blood from Clinical Trial Subjects with Recurrent High Grade Glioma
Date and Time: Thursday, May 5, 6:00-8:00 p.m. ET
Lead Author: Daniel Hogan, Ph.D., bioinformatics scientist at Tocagen

About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information visit www.tocagen.com or follow @Tocagen.